Abiopharma

🔍 Ranade Mandar (Executive)

Company: KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU)

Report Date: 2026-06-30

Detailed Transactions and Holdings:

• Acquired 7,227 shares of Common Stock (Direct)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 19,892.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,800 shares of Common Stock at $36.25 per share (Direct)
  Date: 2026-06-30 | Code: D | equity_swap_involved: 0 | shares_owned_after: 18,092.00 | transaction_form_type: 4
• Sold 1,877 shares of Common Stock at $36.25 per share (Direct)
  Date: 2026-06-30 | Code: F | equity_swap_involved: 0 | shares_owned_after: 16,215.00 | transaction_form_type: 4
• Sold 5,959 shares of Restricted Stock Units FY24 (Derivative)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 536 shares of Restricted Stock Units FY25 (Derivative)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,945.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4
• Sold 732 shares of Restricted Stock Units FY26 (Derivative)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,660.00 | transaction_form_type: 4 | Footnotes: F1, F1, F5, F5

Footnotes:

• F1: Service-based restricted stock units ("RSUs") convert to common stock on a one-for-one basis.
• F2: On June 30, 2026, 3,627 of the reporting person's performance-based RSUs were settled following certification of performance results for the applicable performance period, which resulted in the performance-based RSUs vesting at 150% of target. In the settlement, the reporting person received (a) 3,641 shares and (b) pursuant to an election made by the reporting person, cash in settlement of RSUs otherwise entitling the reporting person to receive 1,800 shares. In addition, on June 30, 2026, 518 of the reporting person's service-based RSUs vested. Accordingly, the reporting person received 4,159 shares in the aggregate as a result of the settlement of these RSUs, as well as a payment in cash in lieu of 1,800 shares.
• F3: On June 28, 2023, the reporting person was granted RSUs that vest as follows: (a) 30% of the number of RSUs subject to the award consisted of service-based RSUs that vested in three equal annual installments beginning on June 30, 2024, subject to the reporting person's continued employment with the Company, and (b) 70% of the number of RSUs subject to the award consisted of performance based RSUs that vested only if performance goals were achieved over a three-year period. The actual number of shares (if any) received upon settlement of the performance-based RSUs depended on continued employment and actual performance over the three-year period.
• F4: On June 28, 2024, the reporting person was granted RSUs that vest as follows: (a) 40% of the number of RSUs subject to the award consisted of service-based RSUs that vest in three equal annual installments beginning on June 30, 2025, subject to the reporting person's continued employment with the Company, and (b) 60% of the number of RSUs subject to the award consisted of performance based RSUs that vest only if performance goals were achieved over a three-year period. The actual number of shares (if any) received upon settlement of the performance-based RSUs depends on continued employment and actual performance over the three-year period.
• F5: On June 25, 2025, the reporting person was granted RSUs that vest as follows: (a) 50% of the number of RSUs subject to the award consisted of service-based RSUs that vested in three equal annual installments beginning on June 30, 2026, subject to the reporting person's continued employment with the Company, and (b) 50% of the number of RSUs subject to the award consisted of performance based RSUs that vested only if performance goals were achieved over a three-year period. The actual number of shares (if any) received upon settlement of the performance-based RSUs depends on continued employment and actual performance over the three-year period.